The Area of research for medical Conditions could be mentioned as:

Immunosuppressive Drug Monitoring, Kidney transplant Recipients Monitoring, Quality and Quantity of Life after Kidney transplantation with respect to pharmacotherapy and surgical methods, adrenal cancer, Benign Prostatic Hyperplasia, Bladder Cancer, Erectile Dysfunction, Hematuria, Kidney Cancer, Kidney Stones, pediatric Urology, Prostate Cancer, Prostatitis, Prosthetic Surgery, Urinary Tract Infection, Genito-Urinary Tract Cancers. Pharmacotherapy after Kidney Transplantation: Cyclosporin and tacrolimus could be mentioned as the main immunosuppressive agents that currently prescribed after kidney transplantation within Iranian population. The wide inter- and intra- variability in pharmacokinetics of such drugs require therapeutic monitoring of concentration. Trough level could be imagined as a surrogate of drug behavior after prescription. Proper linguine for prescription of these drugs should be provided by consideration of drugs behavior in respect to its absorption and elimination by considering the important role of cytochrom P450 in the metabolism phase.

Stimulated by Clinical Study;‎ Encouraged By Sympathetic and Donations

Cytochrome P450 (CYP3A) enzymes are basic for the metabolism of several medications such as tacrolimus, as immunosuppression with tacrolimus in men prevents allograft rejection and reverses steroid-resistant rejection in transplanted recipients. According to a recent publication, more than 100 000 solid organ transplantations are performed every year worldwide. In spite of rapid development associated with the detection of tacrolimus concentrations after organ transplantation, differentiation between the amount of parent drug and drug metabolites seems to be a big challenge. It is well known that tacrolimus metabolic transformations mainly include hydroxylations and demethylations catalysed mostly by members of the cytochrome P450 (CYP) 3A family of haemoproteins. Cytochrome P3A (CYP3A) is the most abundant CYP in human liver, but is also present in high concentrations in enterocytes and in kidney. CYP3A4 activity may vary 4 - 5 fold in human liver (but doses of tacrolimus may vary 14-fold in stable liver recipients reflecting genetic and environmental modulation of enzyme activities in both liver and intestine and contributions from other enzymes. It seems that a higher concentration of metabolite 3 (M-III) may have a nephrotoxic or myelotoxic effect and result in higher frequency of infections.

Subscribe to Isfahan University of Medical Siences RSS